TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change from baseline Brain-Derived Neutrophic Factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline Vascular endothelial growth factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change baseline Magnetic Resonance Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: outcome of pediatric patients with HL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pittsburgh Sleep Quality Index (PSQI) Questionnaire Score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Melatonin Level via Blood Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of patients with myocardial injury after non-cardiac surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total amount of opioids consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Responder rate of overall KOOS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sound-induced sleep disturbances
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: # of Subjects With Altered Gene Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Humidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of response to therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of all serious adverse device/procedure related events
Endpoint domain: Adverse events/effects
Primary endpoint: 3 years disease free survival (DFS)
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline in Standard Uptake Volume (SUV) in the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in VT in the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change in body weight from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Achievement of a reduction in body weight of 5% or more from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to collect left atrial geometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of special attention adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Endurance Shuttle Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of death or relapse bacteremia
Endpoint domain: Mortality/survival
Primary endpoint: Pharmacodynamic effect of pembrolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical outcomes following tonsillectomy and other clinically indicated treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Serum HBV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Serum HBsAg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Serum ALT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of psychotic episode
Endpoint domain: Adverse events/effects
Primary endpoint: WALIDD Primary Dysmenorrhea Intensity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of participants with Partial Response (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of participants with Stable Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of participants with Progressive Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in depressive state
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in symptoms of Post-Concussion Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to alleviation of influenza symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete response within 16 weeks of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lidocaine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lean Tissue Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DOAC trough concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DOAC peak concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operative Death
Endpoint domain: Mortality/survival
Primary endpoint: Graft Leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Nodal staging accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: At least 12 lymph nodes harvested
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of factor inhibitor development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of hepatic malignancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of liver abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Factor activity level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 75% Improvement in Palmoplantar Psoriasis Area and Severity Index (pp-PASI-75) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Static Physician Global Assessment Genitals (s-PGA-G) Score of 0 or 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall treatment success at TOC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: measurement of steatosis by fibroscan examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: measuring serum cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants by Their Preferred Method of Natalizumab Administration at Month 6
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants by Their Preferred Method of Natalizumab Administration at Month 12
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: %TWL at 4 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in the proportion of patients with ALDH1 positive tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pathologic complete response rate after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Gut Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Negative predictive values (NPV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (95% CI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrasound tumor volume measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Composite Adverse Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of COVID-19 vaccination
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pain score at 4 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants losing 5% of their weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chest X-ray abnormality rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with a positive urine culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Total bacterial count in urine samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Duration of recording during positional echography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of positional echography
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Occurrence of eating in the absence of hunger (EAH) episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in stress reaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in intraneural blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of children with intestinal dysbiosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Encephalography measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quadriceps Isometric Knee Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hip abduction Isometric Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Ninety day functional outcomes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Timed 25 Foot Walk Test (T25FW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of participants with dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: percentage of participants with objective response by investigator assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Opening Minds Scale for Health Providers (OMS-HC)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability of Intervention Measure
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Appropriateness of Intervention Measure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total nasal symptoms score (TNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analog scale score (VAS) for rhinitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction level of undetectable HIV patients
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Acceptance level of treatment among undetectable HIV patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quality of life of undetectable HIV patients
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Kcal consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quick Inventory of Depressive Symptomatology (Self-Report; QIDS-SR-16) Change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: World Health Organization Disability Assessment Schedule-II (WHODAS) Change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: The Sheehan Disability Scale (SDS) Change
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of Participants Who Changed Their Choice of Spokesperson
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Coping Styles
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in glutathione concentration of erythrocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in catalase enzyme activity of erythrocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in total antioxidant capacity of plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in thiobarbituric acid reactive substances of plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in protein carbonyls of plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with a change in physical examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with a change in Electrocardiography (ECG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with a change in clinical laboratory evaluations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with a change of Immunogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sensitivity of the InterVenn test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of the InterVenn test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in levels of General Self-Efficacy Scale-10 (GSE-10)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in levels of Basic Psychological Need Satisfaction and Frustration Scale (BPNSFS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hypertrophic Cardiomyopathy symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cornell Musculoskeletal Discomfort Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Nordic Musculoskeletal Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Ratio of Forced expiratory volume in 1 second and Forced Vital Capacity (FEV1/FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Accuracy of tissue lesion screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General Well-Being-Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Physical Performance-Timed Up and Go
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No further bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic activity of inflammatory cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Amount of time spent in PACU
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Death or moderate-or-severe neurodevelopmental disability
Endpoint domain: Mortality/survival
Primary endpoint: Mean Bayley III/IV cognitive score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Voluntary cough peak expiratory flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Vocal fold bowing index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of EEG microstates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Coverage of EEG microstates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean duration of EEG microstates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Follow up for surgical site infection
Endpoint domain: Adverse events/effects
Primary endpoint: Integrated muscle protein synthesis rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Detection of chromosome 10q23 deletion including PTEN locus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Odds ratio of Wolbachia exposure distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Laboratory-confirmed reported dengue case counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Etiology of acute dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Overall hemoglobin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Durable response with hemoglobin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Perceived Subjective Cognitive Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: IP use proportion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: IP use days
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: IP use time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change From Baseline in Overactive Bladder Symptom Score (OABSS) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Red blood cell distribution width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neutrophils to lymphocytes ratio (NLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Platelets to lymphocytes ratio (PLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cervical joint range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of CPD (Cyclobutane Pyrimidine Dimer) lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skills assessment checklist
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prevalence of coexistence between sickle cell anaemia and G6PD deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Geometric Mean Titers (GMT) of anti-P[4], anti-P[6], anti-P[8] rotavirus Immunoglobulin A (IgA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers (GMT) of anti-P[4], anti-P[6], anti-P[8] rotavirus Immunoglobulin G (IgG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers (GMT) of anti-P[4], anti-P[6], anti-P[8] rotavirus neutralizing antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: screening participation rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in PROMIS 6b pain interference scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Differences in the resistome and microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graft Maturity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Economic Status
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Number of in hospital visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Participant Adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Perceived usefulness on institutional risk management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline competence in delivering health-related information and service to service users
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Adherence to the prescribed anti-osteoporotic medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Secondary fracture incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre-colonoscopy state of anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre-colonoscopy pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-colonoscopy pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of dose delivered to dose planned
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Re-hemorrhage rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Serum Concentrations of JNJ-63733657
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in fibrotic and non-fibrotic interstitial opacities on chest HRCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: level of glucose control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Composite Investigator's Global Assessment (IGA) Responder
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain interference with enjoyment of life
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain interference with general activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Achievement rate of HbA1c (≤7%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of suicide attempts (recurrence)
Endpoint domain: Adverse events/effects